AstraZeneca : Health scare in China prompts cautious guidance
>Disappointing year-end in sales and margin - AstraZeneca has just published its Q4 2019 results, which were disappointing both in terms of sales and margin. Despite continued strong growth momentum (sales up 9% cc in the quarter), recent launches have performed less well than expected. Tagrisso undershot expectations by -4%, Lynparza -2% vs consensus and Imfinzi -7% vs the consensus. This disappointment is offset by the strong performance of Symbicort (attractive ba...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.